Molecular Imaging and Therapeutics

The Division of Molecular Imaging and Therapeutics uses imaging probes to diagnose and treat disease. Over the last several decades, this has evolved into increasingly precise evaluations of patients with lymphoma, prostate cancer, neuroendocrine neoplasm, cardiac disease, dementia and metastatic disease. These precise tools are essential for multiple clinical trials with antibodies and small molecules tagged with Lutetium-177, Yttrium-90 and Actinium 225. At the moment, we provide multiple Prostate Cancer therapies with radiolabeled PSMA in conjunction with genitourinary oncology, multiple PET and PET/MR probes investigating Dementia and Neurooncology and are beginning several investigations in Endocrine oncology.  We also offer cardiac PET with N13 Ammonia and specializing in sarcoidosis imaging.

We also offer our services for the pediatric population including a dedicated imaging Child Life Specialist for assessment, preparation before scheduled tests and support for a personalized experience based upon the child and family’s needs.

Clinical equipment includes:

- 2 Siemens mMR PET/MRI Scanners

- 1 GE PET/MR Scanner  

- 1 GE Millenium MPS Single-Head Camera

- 2 GE Optimate 3/8" Crystal, Dual Head Cameras

- 2 GE Discovery 3/8 Crystal, Dual Head SPECT cameras

- 4 Siemens mCT PET/CT Scanners

There is a state-of-the-art cyclotron in the Citicorp Biomedical Imaging Center (CBIC), and many hot cells to produce high quality radiopharmaceuticals with radioisotopes including Carbon-11, Nitrogen-13, Fluorine 18, Zirconium-87, and Iodine-124. Small animal PET and SPECT cameras are available, as are radiopharmaceuticals for study of the dopaminergic and serotonergic system.